<?xml version='1.0' encoding='UTF-8'?><xml><records><record><source-app name="HighWire" version="7.x">Drupal-HighWire</source-app><ref-type name="Journal Article">17</ref-type><contributors><authors><author><style face="normal" font="default" size="100%">Buckley, Rita</style></author></authors><secondary-authors><author><style face="normal" font="default" size="100%">Smolen, Josef S.</style></author></secondary-authors></contributors><titles><title><style face="normal" font="default" size="100%">PRESERVE Trial: Patients with Moderately Active RA Achieve and Maintain Low Disease Activity and Remission with Anti-TNF Therapy More Successfully than Those with High Disease Activity</style></title><secondary-title><style face="normal" font="default" size="100%">MD Conference Express</style></secondary-title></titles><dates><year><style  face="normal" font="default" size="100%">2011</style></year><pub-dates><date><style  face="normal" font="default" size="100%">2011-12-01 00:00:00</style></date></pub-dates></dates><pages><style  face="normal" font="default" size="100%">18-19</style></pages><abstract><style  face="normal" font="default" size="100%">Data from the Randomized, Double-Blind Study Comparing the Safety &amp; Efficacy of Once-Weekly Etanercept 50 mg, Etanercept 25 mg, &amp; Placebo in Combination With Methotrexate in Subjects With Active Rheumatoid Arthritis [PRESERVE; NCT00565409] show that patients with moderately active rheumatoid arthritis (RA) achieve and maintain low disease activity and remission with anti-tumor necrosis factor therapy more successfully than those with high RA activity [Keystone E et al. J Rheumatol 2009].</style></abstract><number><style face="normal" font="default" size="100%">13</style></number><volume><style face="normal" font="default" size="100%">11</style></volume></record></records></xml>